How Do Lung Diseases Raise Aspergillus niger Risk?
At a Glance
COPD, emphysema, bronchiectasis, and prior tuberculosis can damage lung structure and raise the risk of chronic Aspergillus disease, but a positive Aspergillus niger sputum culture may only show harmless colonization. Symptoms, CT changes, and blood tests help determine whether treatment is needed.
In this answer
4 sections
If you have structural lung disease—conditions that have permanently changed the architecture of your lungs, such as chronic obstructive pulmonary disease (COPD), emphysema, bronchiectasis, or a history of tuberculosis—your risk for chronic Aspergillus infections is higher. While Aspergillus fumigatus is the most common cause, Aspergillus niger can also be involved.
However, finding A. niger in your sputum (phlegm) does not automatically mean you have an active infection. Because these fungi are common in the environment, they can temporarily land in your airways or live there without causing harm, a state known as colonization [1][2]. A true infection, such as chronic pulmonary aspergillosis (CPA), requires medical evaluation and develops when the fungus takes advantage of pre-existing lung damage [3][4].
What This Means For You: A positive A. niger culture is just a finding. Your clinician will determine whether it is harmless colonization or active disease by evaluating your symptoms, CT scan changes, and additional test results.
How Lung Damage Invites Infection
Healthy lungs have smooth airways and robust defense mechanisms that clear out inhaled fungal spores. Underlying lung conditions alter this environment, creating spaces where Aspergillus niger can persist and grow:
- Cavities and Scarring: Prior tuberculosis or severe lung infections can leave behind empty spaces (cavities) or areas of fibrosis (permanent lung scarring) [3][5]. Aspergillus spores can settle into these sheltered cavities and sometimes grow into a tangled mass known as a fungal ball (aspergilloma) [6].
- Enlarged Air Spaces: Emphysema destroys the delicate air sacs in the lungs, creating abnormally large, damaged spaces where the fungus can more easily take hold [3][7].
- Impaired Mucus Clearance: Bronchiectasis causes airways to become permanently widened and weakened. This damage impairs your lungs’ ability to clear mucus, allowing fungal spores to become trapped in the airways [8][9].
Additionally, the treatments often used for these conditions can affect your risk. Systemic corticosteroids (steroid pills or IVs) and high-dose inhaled steroids suppress your immune system, while repeated courses of antibiotics alter the balance of microbes in your airways [10][11]. Important: Never stop or change your corticosteroid medications without your doctor’s supervision, as abrupt changes can be dangerous [12].
Understanding the Different Stages
A positive A. niger culture can mean several different things depending on your specific situation:
| Stage | What It Is | Typical Signs | What It Means |
|---|---|---|---|
| Colonization | The fungus lives in the airways but isn’t causing disease [1]. | No new symptoms; no new CT changes. | Often requires no antifungal treatment, just observation [1]. |
| Aspergilloma | A “fungal ball” growing inside an existing lung cavity [6]. | May cause no symptoms, or can cause coughing up blood [4]. | May just be monitored, or might require treatment if it causes bleeding. |
| Chronic Pulmonary Aspergillosis (CPA) | A slow-moving, active infection damaging the lung tissue [3]. | Worsening cough, weight loss, fatigue, new cavities or nodules on CT [13]. | Requires specialist review and often long-term oral antifungal medication [4]. |
Diagnosing Active Infection (CPA)
Unlike acute infections, CPA develops gradually over months or years [13]. Because symptoms overlap with your baseline COPD or bronchiectasis, separating fungal symptoms from your usual baseline can be stressful. Your doctor is looking for specific changes from your normal health. Diagnosis involves a combination of factors:
- Symptoms: A compatible illness lasting for months. Symptoms might include a worsening chronic cough, breathlessness, unexplained weight loss, fatigue, fever, or chest pain [7][14].
- Imaging: A chest CT scan showing progressive cavities, fungal balls, nodules, pleural thickening, or pericavitary infiltrates [4][13].
- Blood Tests: An Aspergillus IgG blood test looks for antibodies to see if your immune system is actively fighting the fungus. While a positive result supports the diagnosis, it does not absolutely prove active infection (it can reflect past exposure), and a negative result doesn’t completely rule it out [3][15].
A Warning on Coughing Up Blood (Hemoptysis)
Coughing up blood can be a symptom of CPA, an aspergilloma, or your underlying bronchiectasis [4][14].
Emergency Action: If you experience increasing or persistent bleeding, cough up more than small streaks (e.g., clots or larger amounts), or if the bleeding is accompanied by severe breathlessness, dizziness, fainting, or chest pain, seek emergency medical care immediately [4]. Even small, recurrent amounts of blood should be reported promptly to your care team.
Next Steps and Supporting Your Lungs
If A. niger is found and your doctor suspects active disease, you will likely be referred to a respiratory or infectious disease specialist. If CPA is diagnosed, treatment often involves prolonged oral antifungal therapy, which requires regular monitoring for drug interactions and liver function [4][16].
While you cannot entirely prevent Aspergillus exposure, you can support your general lung health. These measures won’t cure or guarantee prevention of a fungal infection, but they help manage your underlying disease:
- Medication Review: Have your doctor review your need for corticosteroids and antibiotics to ensure the benefits outweigh the risks [12][11].
- Airway Clearance: If you have bronchiectasis, regularly clearing mucus reduces exacerbations [17]. Use bronchodilators (inhalers that relax and open airways) as prescribed.
- General Health: Quitting smoking and getting vaccinated (like flu, pneumococcal, and COVID-19 vaccines) helps prevent other respiratory illnesses that could further damage your lungs [5][12].
Common questions in this guide
Can COPD, emphysema, bronchiectasis, or past tuberculosis increase Aspergillus risk?
Does finding Aspergillus niger in sputum mean I have a lung infection?
How do doctors diagnose chronic pulmonary aspergillosis?
What is the difference between Aspergillus colonization, an aspergilloma, and CPA?
When is coughing up blood from a lung problem an emergency?
Should I stop my steroid medicine if Aspergillus is found?
What treatment might be needed for chronic pulmonary aspergillosis?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About fungal risk
Does having an underlying lung condition change my risk from this fungus?
What the result means
Will my clinician check whether this finding is harmless colonization or active disease?
Symptoms to watch
Which symptoms would make my care team check for active infection?
Related questions
Show more
Get notified when new evidence is published on Aspergillus niger infection.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
[Aspergillus in airway material : Ignore or treat?]
Salzer HJF, Lange C, Hönigl M
Der Internist 2017; (58(11)):1150-1162 doi:10.1007/s00108-017-0334-9.
PMID: 28986661 - 2
Non-fumigatus Aspergillus-associated pulmonary events: a diagnostic challenge.
Godet C, Joste V, Frat J-P, et al.
Journal of clinical microbiology 2026; (64(4)):e0016326 doi:10.1128/jcm.00163-26.
PMID: 41848336 - 3
Chronic Pulmonary Aspergillosis: Clinical Presentation and Management.
Evans TJ, Lawal A, Kosmidis C, Denning DW
Seminars in respiratory and critical care medicine 2024; (45(1)):88-101 doi:10.1055/s-0043-1776914.
PMID: 38154471 - 4
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.
Denning DW, Cadranel J, Beigelman-Aubry C, et al.
The European respiratory journal 2016; (47(1)):45-68 doi:10.1183/13993003.00583-2015.
PMID: 26699723 - 5
Secondary infections following tuberculosis: epidemiology, pathogenesis and clinical implications.
Cortacans M, Gogichadze N, Soldevilla P, et al.
Breathe (Sheffield, England) 2026; (22(1)):250055 doi:10.1183/20734735.0055-2025.
PMID: 41607634 - 6
Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran.
Hedayati MT, Azimi Y, Droudinia A, et al.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2015; (34(9)):1759-65 doi:10.1007/s10096-015-2409-7.
PMID: 26003310 - 7
Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis.
Zhong H, Wang Y, Gu Y, et al.
Frontiers in medicine 2022; (9()):811807 doi:10.3389/fmed.2022.811807.
PMID: 35223906 - 8
Bronchiectasis complicated by pulmonary aspergillosis: a multicenter study on prognosis and risk factors.
Yang J, Wang X, Lu S, et al.
Journal of thoracic disease 2025; (17(11)):9827-9835 doi:10.21037/jtd-2025-1139.
PMID: 41376918 - 9
Aspergillus-Associated Endophenotypes in Bronchiectasis.
Jaggi TK, Ter SK, Mac Aogáin M, Chotirmall SH
Seminars in respiratory and critical care medicine 2021; (42(4)):556-566 doi:10.1055/s-0041-1730947.
PMID: 34261180 - 10
The emergence of Aspergillus species in chronic respiratory disease.
Yii AC, Koh MS, Lapperre TS, et al.
Frontiers in bioscience (Scholar edition) 2017; (9(1)):127-138 doi:10.2741/s477.
PMID: 27814579 - 11
COPD and Aspergillus-a complex interaction of global health importance.
Denning DW, Bertuzzi M, Chotirmall SH, et al.
The Lancet. Infectious diseases 2026; doi:10.1016/S1473-3099(26)00360-9.
PMID: 42612667 - 12
Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.
Denning DW, Rogers TR, Takazono T, et al.
American journal of respiratory and critical care medicine 2026; doi:10.1093/ajrccm/aamag310.
PMID: 42384914 - 13
Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings.
Denning DW, Page ID, Chakaya J, et al.
Emerging infectious diseases 2018; (24(8)) doi:10.3201/eid2408.171312.
PMID: 30016256 - 14
Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients.
Hou X, Zhang H, Kou L, et al.
Medicine 2017; (96(42)):e8315 doi:10.1097/MD.0000000000008315.
PMID: 29049239 - 15
Improving Diagnostic Sensitivity of Chronic Pulmonary Aspergillosis Using Species-Specific IgG.
Sehgal IS, Agarwal R, Muthu V, et al.
Mycoses 2025; (68(9)):e70107 doi:10.1111/myc.70107.
PMID: 40899055 - 16
Chronic Pulmonary Aspergillosis Following Nontuberculous Mycobacterial Infections: An Emerging Disease.
Phoompoung P, Chayakulkeeree M
Journal of fungi (Basel, Switzerland) 2020; (6(4)) doi:10.3390/jof6040346.
PMID: 33302348 - 17
Interventions to reduce the impact of post-tuberculosis lung disease: a scoping review of the literature.
Byrne AL, Günther G, Tadyanemhandu C, et al.
BMC pulmonary medicine 2026; (26(1)).
PMID: 42243811
This page is for informational purposes only and does not constitute medical advice. Ask your respiratory or infectious disease clinician to interpret your symptoms, test results, and scans and guide your treatment.